Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study
Authors
Keywords
-
Journal
Targeted Oncology
Volume 13, Issue 6, Pages 715-724
Publisher
Springer Nature
Online
2018-11-29
DOI
10.1007/s11523-018-0605-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MTOR inhibitor-based combination therapies for pancreatic cancer
- (2018) Zonera Hassan et al. BRITISH JOURNAL OF CANCER
- Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis
- (2017) Gui-Feng Liu et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis
- (2017) Xiu-Wei Zhang et al. Targeted Oncology
- A phase I study of temsirolimus in combination with gemcitabine in previously untreated metastatic pancreatic cancer.
- (2017) Jason Edward Faris et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting mTOR in Pancreatic Ductal Adenocarcinoma
- (2016) Sentia Iriana et al. Frontiers in Oncology
- Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer
- (2015) S. Kordes et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Therapeutic Advances in Pancreatic Cancer: Miles to Go Before We Sleep
- (2015) T. Bekaii-Saab et al. JNCI-Journal of the National Cancer Institute
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- Therapeutic Advances in Pancreatic Cancer: Miles to Go Before We Sleep
- (2015) T. Bekaii-Saab et al. JNCI-Journal of the National Cancer Institute
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis
- (2013) Jian Xu et al. CURRENT MEDICAL RESEARCH AND OPINION
- Different Patterns of Akt and ERK Feedback Activation in Response to Rapamycin, Active-Site mTOR Inhibitors and Metformin in Pancreatic Cancer Cells
- (2013) Heloisa P. Soares et al. PLoS One
- Incidence and Risk of Treatment-Related Mortality with mTOR Inhibitors Everolimus and Temsirolimus in Cancer Patients: A Meta-Analysis
- (2013) Wei-Xiang Qi et al. PLoS One
- Gemcitabine confirmed as the first-line therapy for pancreatic cancer
- (2011) Claire Greenhill Nature Reviews Gastroenterology & Hepatology
- PI3K/AKT/mTOR Pathway in Angiogenesis
- (2011) Jayashree Karar et al. Frontiers in Molecular Neuroscience
- Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
- (2010) I Garrido-Laguna et al. BRITISH JOURNAL OF CANCER
- Gemcitabine-based Cytotoxic Doublets Chemotherapy for Advanced Pancreatic Cancer: Updated Subgroup Meta-analyses of Overall Survival
- (2010) D. r. Xie et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- PTEN regulate angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells
- (2009) Jiachi Ma et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells
- (2007) Amalia Azzariti et al. BIOCHEMICAL PHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started